Cardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Soft tissue sarcoma (STS) is a rare cancer requiring diverse treatments.
• Doxorubicin is a key chemotherapy agent for STS but poses cardiotoxicity risks.
• Understanding doxorubicin's cardiac impact is vital for patient outcomes.

Purpose of the Study:

• Evaluate doxorubicin's effect on cardiac function in sarcoma patients.
• Identify risk factors associated with doxorubicin-induced cardiotoxicity.
• Correlate cardiotoxicity with patient demographics and treatment variables.

Main Methods:

• Retrospective analysis of 133 sarcoma patients treated with doxorubicin (2016-2022).
• Collected data included demographics, comorbidities, cardiac measurements, and treatment details.
• Statistical analysis assessed cardiotoxicity associations.

Main Results:

• Cardiotoxicity occurred in 9% of patients.
• Female sex and higher ECOG performance status increased cardiotoxicity risk.
• Cardiotoxicity was linked to higher mortality risk; overall survival was 18 months.

Conclusions:

• Doxorubicin-induced cardiotoxicity is a significant concern in sarcoma treatment.
• Female patients and those with higher ECOG status require closer cardiac monitoring.
• Further research is needed for preventive strategies against doxorubicin cardiotoxicity.